NICE: updated guidelines on lung cancer

  • National Institute for Health and Care Excellence

  • Oncology guidelines update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

NICE has issued updated guidelines on the diagnosis and management of lung cancer, which include new recommendations on intrathoracic lymph node assessment, brain imaging in non-small-cell lung cancer (NSCLC), and radical radiotherapy for NSCLC, as well as new guidance on chemoradiotherapy and surgery for stage IIIA-N2 NSCLC and thoracic radiotherapy and prophylactic cranial irradiation for small-cell lung cancer (SCLC).

Key recommendations include:

  • PET-CT is preferred for intrathoracic lymph node assessment after CT for nodes
  • PET-CT followed by EBUS‑TBNA and/or EUS‑FNA for nodes ≥10.
  • Contrast-enhanced brain CT for stage II NSCLC.
  • Contrast-enhanced brain MRI for stage III NSCLC.
  • Where lobectomy is not performed, offer radical radiotherapy with stereotactic ablative radiotherapy (SABR) or sublobar resection.
  • If SABR is contraindicated, offer conventional or hyperfractionated radiotherapy.
  • For stage IIIA or IIIB NSCLC patients who cannot tolerate or who decline chemoradiotherapy, consider radical radiotherapy.
  • Follow the SABR Consortium guidance on fractionation.
  • For conventionally fractionated radical radiotherapy, administer 55 Gy in 20 fractions over four weeks or 60-66 Gy in 30-33 fractions over 6-6½ weeks.
  • Do not offer neo-adjuvant treatment for operable stage I-II NSCLC outside of clinical trial.
  • Consider chemoradiotherapy with surgery (3-5 weeks later) for operable stage IIIA-N2 NSCLC.
  • Consider thoracic radiotherapy with prophylactic cranial irradiation for extensive-stage SCLC with partial or complete response to chemotherapy within the thorax and at distant sites.
  • Consider prophylactic cranial irradiation for extensive-stage disease SCLC and WHO performance status 0 to 2, if the disease has responded to first-line treatment.

NICE has produced algorithms covering systemic treatment options for stage IIIB and IV non-squamous (adenocarcinoma, large cell undifferentiated) cancer and NSCLC (not otherwise specified), and for stage IIIB and IV squamous NSCLC.

Recommendations are also provided in relation to EGFR-TK status, ALK gene rearrangement, PDL1 status, and ROS1 positivity.